Lung Transplant, Physiotherapy, Sarcopenia
Conditions
Brief summary
In France, the profile of patients receiving lung transplants has changed in recent years, mainly due to the advent of treatment for cystic fibrosis. This progress has led to an evolution in the patient profile, with an increase in cases of pulmonary fibrosis or COPD, and an increase in the average age of patients. In these older patients, sarcopenia, a condition characterized by loss of muscle mass, is a major concern, as it exacerbates morbidity and mortality. After transplantation, patients are at risk of developing neuromyopathy due to their hospitalization in intensive care. There is currently no effective preventive treatment for this condition, underlining the need for early rehabilitation strategies. The combination of sarcopenia and neuromyopathy diminishes their functional capabilities on discharge from the ICU. Muscle ultrasound, a simple, non-invasive technique, is already used to assess muscle function in intensive care patients. This study aims to evaluate the use of ultrasound to measure muscle loss in lung transplant patients, in particular by examining the rectus femoris muscle. Objectives include observing variations in the surface area of the rectus femoris muscle before and after transplantation, identifying factors influencing this variation, and exploring its relationship with post-transplant morbidity. In summary, this study seeks to better understand muscle loss in lung transplant patients using ultrasound, in order to identify risk factors and guide the development of post-transplant rehabilitation strategies.
Interventions
OTHERultrasound measurement of the cross-sectional area of the rectus femoris
ultrasound measurement of the cross-sectional area of the rectus femoris at D-1 and D+3, +7 , +14
Sponsors
Hopital Foch
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient over the age of 18 * Patient registered on the lung transplant list at Hôpital Foch for a single or double-lung transplant * Patient who did not object to inclusion in the study * Patient affiliated to a French health insurance plan
Exclusion criteria
* Patient listed for a combined transplant (heart-lung, liver-lung, lung-kidney) * Patient on national priority list (super-emergency) * Pregnant or breast-feeding patient * Patient under guardianship
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the change at D7 in the cross-sectional area of the rectus femoris following lung transplantation | Baseline and Day 7 |
Secondary
| Measure | Time frame |
|---|---|
| Measure change in cross-sectional area of the rectus femoris at D7 according to LT pattern | Baseline and day 14 |
| Evaluate the relationship between length of stay in intensive care unit and variation in cross-sectional area of the rectus femoris at D7 | Baseline and day 7 |
| Determine the relationship between cross-sectional area of the rectus femoris at D-1 and Body Mass Index | Baseline |
Countries
France
Outcome results
None listed